| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | certepetide (formerly LSTA1) — imaging study (Kuva collaboration) Imaging of tumor uptake/PK (mechanism validation) in humans | Phase 1 | — | Subscribe to access the data. | Peptides | Oncology | |
Phase 1 data readout example | certepetide (formerly LSTA1) — imaging study (Kuva collaboration) Imaging of tumor uptake/PK (mechanism validation) in humans | Phase 1 | — | Subscribe to access the data. | Peptides | Oncology | |
Phase 1 data readout example | certepetide (formerly LSTA1) — imaging study (Kuva collaboration) Imaging of tumor uptake/PK (mechanism validation) in humans | Phase 1 | — | Subscribe to access the data. | Peptides | Oncology |
Recent Updates
Recently added Catalysts
Lisata Therapeutics, Inc.$3.27
+0.04 (+1.08%)
C 50Pipeline Score Undervalued Pharma · Commercial
Market Cap
28.59 M
EPS
-1.86
P/E Ratio
-
Value Trade
170.60 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
-
R&D Expenses
1.20 M
Operating CF
-3.08 M
Total Assets
14.06 M
Total Liabilities
3.39 M
Equity
10.93 M
D/E Ratio
12,345
3.97 %
Week
-1.57 %
1 Month
-30.53 %
3 Month
59.39 %
6 Month
-86.04 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
14.06 M
Monthly Burn
1.03 M
Runway
11.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
63.17 K
52 Week Range
1.81 - 5.07
% held by Insiders
18.68 %
% held by Institutions
11.61 %
Enterprise Value
15.28 M
Total Shares
8.83 M
Short %
1.21 %
Float Shares
6.63 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lisata Therapeutics, Inc.
517Total events
9Upcoming
130Tier-1 (high impact)
2010 – 2041Coverage
Upcoming catalysts 9
TBD
T2Trial Completion
Qilu to complete and wind down ongoing Phase 2 study of certepetide in metastatic pancreatic ductal adenocarcinoma
Event history 508
Jun 10, 2026
◆AcquisitionCorporate
Kuva Labs commences tender offer to acquire Lisata for $4.00/share plus CVR
May 2026
◆Timing GuidancePresentation
Company expects to announce numerous milestones over next 1.5 years
Apr 2, 2026
◆AcquisitionCorporate
Waiver to Agreement and Plan of Merger between Kuva Labs and Lisata Therapeutics
Jan 27, 2026
▲Partnership / LicensecertepetideCorporate
Mutual termination of license agreement with Qilu Pharmaceutical for certepetide in Greater China
Jan 21, 2026
◆AcquisitionCorporate
Lisata enters binding term sheet to be acquired by Kuva Labs for $4.00 per share in all-cash tender offer
Q1 2026
◆Trial InitiationTrial
OUD drug candidate targeted to enter Phase 1 human trials early next year
opioid use disordersource ↗
2026
●Timing GuidancecertepetidePresentation
Steady flow of additional data anticipated through remainder of 2025 and into 2026
solid tumorssource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $152M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored15.0x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 911)
Percentile RankLisata Therapeutics, Inc. carries a moderate pipeline score (50/100), with $8.9B risk-adjusted pipeline value, led by CLBS03 Low Dose in Diabetes Mellitus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLBS03 Low Dose Monoclonal antibody | Diabetes Mellitus | Phase 2 | NCT02691247 | 33% | $6.9B | COMPLETED | 113 | - | - | Jan 1, 2020 | - | Jan 8, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
certepetide OrphanRare Pediatric | pancreatic cancer | Phase 1/2a | 2025-09-29 | R0 resection rate: 50%; two year overall survival rate: 60%; pathologic partial response: 70%; median disease free survival: 12 months Read More | Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial Read More | |
certepetide OrphanRare Pediatric | pancreatic cancer | Phase 1/2a | 2025-09-29 | R0 resection rate: 50%; two year overall survival rate: 60%; pathologic partial response: 70%; median disease free survival: 12 months Read More | Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial Read More | |
certepetide OrphanRare Pediatric | pancreatic cancer | Phase 1/2a | 2025-09-29 | R0 resection rate: 50%; two year overall survival rate: 60%; pathologic partial response: 70%; median disease free survival: 12 months Read More | Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LSTA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LSTA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LSTALisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata Therapeutics has announced a tender offer by Kuva Labs Inc. to acquire all outstanding shares for $4.00 each, plus contingent value rights. The deal, which values Lisata at a premium, is recommended by its Board of Directors and is expected to close in Q3 2026, pending certain conditions. Additional cash payments may be available based on milestone achievements.
Read more →LSTAWAIVER TO AGREEMENT AND PLAN OF MERGER This WAIVER TO AGREEMENT AND PLAN OF MERGER (this " Waiver "), dated
Kuva Labs Inc., along with its wholly owned subsidiary Kuva Acquisition Corp. and Lisata Therapeutics, Inc., has executed a waiver to the agreement and plan of merger originally dated March 6, 2026. This waiver extends the time for commencing the Offer as stipulated in the merger agreement, indicating a cooperative approach among the parties involved. The document outlines the signing by key executives from all companies, reinforcing their commitment to the merger process.
Read more →LSTA▲ +20.6%on this news
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Lisata Therapeutics has entered into a definitive agreement to be acquired by Kuva Labs, Inc. Stockholders will receive $5.00 per share in cash and a contingent value right for potential additional payments. The board of directors unanimously recommends acceptance of the offer, which is expected to close in the second quarter of 2026, pending customary conditions.
Read more →LSTALisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additio
Lisata Therapeutics has entered into a definitive agreement for acquisition by Kuva Labs, Inc., under which Lisata stockholders will receive $5.00 per share in cash at closing, with the potential for additional compensation through a contingent value right. The transaction, recommended by Lisata's board, is expected to close in the second quarter of 2026, following the necessary tender conditions. Post-acquisition, Lisata will transition to a privately-held structure, with its stock delisted from Nasdaq.
Read more →LSTALisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata Therapeutics has mutually terminated its license agreement with Qilu Pharmaceutical for certepetide, regaining full development rights in Greater China. This decision allows Lisata to explore further development of its proprietary peptide product candidate. Qilu will continue its ongoing Phase 2 clinical study of certepetide in pancreatic cancer, and Lisata will negotiate for relevant study data.
Read more →LSTA▲ +86.6%on this news
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Lisata Therapeutics has entered a term sheet to be acquired by Kuva Labs for $4.00 per share in cash, representing an 85% premium over its recent stock price. Stockholders will also receive contingent value rights worth $1 per share upon achieving specific milestones. The acquisition is expected to enhance the development of Lisata's promising product candidate, certepetide.
Read more →LSTA▼ -12.3%on this news
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics reported its third quarter 2025 financial results, highlighting positive clinical data for certepetide from various trials. The company formed a strategic alliance with GATC Health for AI-driven drug discovery and entered a global license agreement with Catalent. Operating expenses decreased, and the company projects sufficient cash to fund operations into early 2027.
Read more →LSTALisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
Lisata Therapeutics has been awarded the 'Overall BioPharma Solution of the Year' at the BioTech Breakthrough Awards for its innovative CendR Platform technology. This recognition marks the second consecutive year for Lisata, which has achieved significant clinical results in treating advanced solid tumors. The company's approach aims to improve drug delivery and efficacy in cancer therapies, particularly for pancreatic cancer.
Read more →LSTA▼ -5.3%on this newsshared move
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Lisata Therapeutics announced positive preclinical results for certepetide, presented by its partner Catalent at the World ADC Conference. The data indicates that certepetide enhances the efficacy of antibody-drug conjugates (ADCs) while improving the distribution of cytotoxic agents within tumors. This reinforces Lisata's strategy to leverage certepetide's unique properties in cancer treatment.
Read more →LSTALisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced it will report its third-quarter financial results for 2025 on November 6, 2025, followed by a conference call. The company specializes in innovative therapies for advanced solid tumors, particularly focusing on its investigational drug certepetide. Lisata has established significant partnerships and anticipates key milestones over the next one and a half years, with sufficient funding to support operations into early 2027.
Read more →LSTAForward-looking statements advisory This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation R
Lisata Therapeutics has issued a presentation highlighting forward-looking statements that pose substantial risks and uncertainties under the Private Securities Litigation Reform Act. The company focuses on developing therapies for cancer, notably its lead candidate, certepetide, which aims to improve treatment for solid tumors. Management outlines their financial stability, with a cash runway until early 2027. However, various factors, including regulatory challenges and market conditions, could impact future performance significantly.
Read more →LSTALisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics and Catalent have entered a global licensing agreement allowing Catalent to use Lisata's certepetide in antibody-drug conjugates (ADCs). This collaboration aims to develop targeted therapies for difficult-to-treat diseases, leveraging positive preclinical results. Lisata stands to receive significant milestone payments and revenue sharing from future sales.
Read more →LSTALisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Lisata Therapeutics announced promising preliminary results from the pancreatic cancer cohort of the Phase 1/2a CENDIFOX trial, evaluating certepetide combined with FOLFIRINOX. The trial showed a 50% R0 resection rate and a 60% two-year overall survival rate among patients. Findings will be presented at the AACR Special Conference, highlighting the potential of certepetide to improve treatment outcomes for pancreatic cancer.
Read more →LSTALisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. CEO David J. Mazzo, Ph.D., will provide a corporate overview through a pre-recorded presentation available on-demand starting September 5, 2025. The company is focused on developing therapies for advanced solid tumors and has promising product candidates.
Read more →LSTA▼ -5.4%on this news
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next d
Lisata Therapeutics reported its financial results for Q2 2025, highlighting a cash runway extending into the fourth quarter of 2026 with no debt. The company continues to advance its clinical development portfolio, particularly with its product candidate certepetide, showing promising preliminary results from recent trials. Key milestones for various ongoing studies are expected in the near future, reinforcing the potential of certepetide in treating advanced solid tumors. A conference call will be held after the announcement to discuss these developments in detail.
Read more →LSTALisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics, Inc. announced that it will report its second quarter financial results for 2025 on August 7, 2025, followed by a conference call. The company is focused on developing therapies for advanced solid tumors and expects to reach significant milestones over the next year and a half. Their investigational drug, certepetide, aims to improve targeting and penetration of solid tumors. Lisata believes it has adequate funding to support operations into late 2026 with ongoing clinical trials.
Read more →LSTA▼ -6.2%on this news
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
Lisata Therapeutics and WARPNINE have completed patient enrollment in the Phase 1b/2a iLSTA trial, which evaluates certepetide in combination with standard chemotherapy and immunotherapy for locally advanced pancreatic cancer. Preliminary data presented at ESMO-GI indicates a 60% overall response rate and a 100% disease control rate. The trial aims to provide a new treatment option for patients with non-resectable PDAC.
Read more →LSTALisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent
Lisata Therapeutics has been granted a new U.S. patent for its drug certepetide, extending intellectual property protection until 2040. This composition of matter patent safeguards the chemical structure and related technologies of certepetide, which is designed for treating solid tumors. The patent not only enhances Lisata's overall IP portfolio but also offers long-term market exclusivity, thereby strengthening its strategic position for partnerships and commercialization. Certepetide has shown promising results in previous clinical trials, particularly in enhancing the delivery of anti-cancer treatments and modifying the tumor microenvironment.
Read more →LSTA▲ +16.7%on this news
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata's Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer ASCEND co
Lisata Therapeutics presented positive preliminary results from Cohort B of the ASCEND trial, evaluating their investigational drug, certepetide, for metastatic pancreatic cancer. The study revealed a significant improvement in progression-free survival and overall survival rates for patients treated with certepetide compared to those receiving the placebo. The findings support the potential of certepetide as a novel therapy in the ongoing fight against this deadly cancer. Final data from both cohorts of the ASCEND study are expected to be available later this year.
Read more →LSTALisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
Lisata Therapeutics has expanded its alliance with GATC Health to improve AI-driven drug discovery. The collaboration focuses on advancing a new therapeutic for opioid use disorder (OUD) into human clinical trials by early 2026. Lisata will leverage GATC's AI-powered Multiomics Advanced Technology platform to enhance its drug pipeline and optimize the drug development process. The strategic relationship positions both companies for potential success in bringing novel therapies to market faster and more efficiently.
Read more →LSTALisata Therapeutics to Present at the 2025 BIO International Convention
Lisata Therapeutics, Inc. is set to present a corporate overview at the 2025 BIO International Convention in Boston, MA from June 16 to 19. CEO David J. Mazzo will discuss the company's progress and innovative therapies for advanced solid tumors, including their investigational drug, certepetide. The company anticipates delivering multiple key milestones in the upcoming year and is well-funded to continue its operations into late 2026. Lisata is recognized for its groundbreaking approach to enhancing cancer treatment through its unique technology platform.
Read more →LSTALisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025 Cohort B results from the ASCEND trial ac
Lisata Therapeutics reported its financial results for Q1 2025, highlighting significant progress in its clinical development. Positive data from Cohort A of the ASCEND trial were presented at ASCO-GI 2025, and Cohort B results are set for oral presentation at ESMO-GI 2025. The company also noted a cash runway extending into Q3 2026, allowing continued advancement of its therapy, certepetide, across various solid tumors. Upcoming conversations with regulatory agencies are planned to guide the next steps for certepetide's development.
Read more →LSTALisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
Lisata Therapeutics, a clinical-stage pharmaceutical company, will report its financial results for Q1 2025 on May 8, 2025. The company plans to host a conference call at 4:30 p.m. ET, and participants are encouraged to register in advance. Lisata is developing innovative therapies for advanced solid tumors and anticipates announcing several milestones related to its clinical trials in the coming months. The financial outlook suggests that their capital will support operations into the second quarter of 2026.
Read more →LSTA▲ +10.7%on this news
Lisata Therapeutics Announces Research License with Catalent
Lisata Therapeutics has entered into a research license agreement with Catalent to explore the efficacy of its cyclic peptide product candidate, certepetide, in combination with Catalent's SMARTag® antibody-drug conjugate technology. Catalent will manage the research expenses while Lisata provides consulting support. The collaboration aims to improve treatment strategies for advanced solid tumors, potentially revolutionizing precision oncology. Additionally, the agreement aligns with Lisata's strategy to maximize certepetide's therapeutic potential and capitalize on upcoming clinical trial milestones.
Read more →LSTALisata Therapeutics to Present at the Investival Showcase USA
Lisata Therapeutics, a clinical-stage pharmaceutical company, has announced that its CEO, Dr. David J. Mazzo, will present a corporate overview at the Investival Showcase USA on March 11, 2025. The company focuses on developing therapies for advanced solid tumors and other serious diseases, utilizing its investigational product candidate, certepetide. Lisata has reported establishing significant partnerships and anticipates announcing several milestones over the next year and a half related to its clinical trials. The expected funding is projected to sustain operations through the second quarter of 2026.
Read more →LSTA▲ +10.2%on this newsshared move
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
Lisata Therapeutics and GATC Health have initiated a strategic collaboration focusing on using AI to improve drug development processes, particularly for Lisata's investigational product, certepetide. GATC's Multiomics Advanced Technology platform will analyze certepetide to optimize its development for various indications. The partnership seeks to reduce traditional biopharmaceutical risks and enhance the efficiency of clinical trials, ultimately increasing the success probability of drug candidates. Lisata's operational expertise is also set to support GATC in advancing its own drug pipeline.
Read more →LSTALisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming mo
Lisata Therapeutics has reported its full year 2024 financial results alongside a business update, highlighting promising preliminary data from its Phase 2b ASCEND trial for pancreatic cancer. The company announced that Cohort A of the trial demonstrated a positive trend in overall survival with complete responses in the treatment group. Lisata is advancing its development portfolio, focusing on the investigational therapy certepetide, with multiple ongoing and planned studies. The company also has sufficient cash to support operations through the second quarter of 2026.
Read more →LSTALisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced it will report its financial results for the year ending December 31, 2024, on February 27, 2025, followed by a conference call at 4:30 p.m. Eastern time. The company focuses on developing therapies for advanced solid tumors and other serious diseases, with a specific candidate, certepetide, aimed at improving targeted drug delivery. They anticipate significant milestones over the next 1.5 years and believe they have sufficient funding until the second quarter of 2026.
Read more →LSTALisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, announced that CEO David J. Mazzo will present at the 2025 BIO CEO & Investor Conference on February 10. This opportunity highlights the company's ongoing commitment to addressing serious diseases through its investigational drug, certepetide. The company anticipates significant milestones in the next 1.5 years, supported by existing capital. The conference will take place at the New York Marriott Marquis in New York City.
Read more →LSTA▼ -11.6%on this news
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics and WARPNINE Incorporated have reported promising preliminary results from their Phase 1b/2a iLSTA trial, which evaluates the investigational drug certepetide in combination with standard chemotherapy and immunotherapy for patients with locally advanced non-resectable pancreatic ductal adenocarcinoma. The results indicate positive responses among patients, with several achieving partial and complete responses. These findings underscore the potential of certepetide to significantly improve treatment outcomes in this challenging patient population. The preliminary data will be presented at the upcoming ASCO Gastrointestinal Cancers Symposium in January 2025.
Read more →LSTA▼ -29.5%on this newsshared move
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma Cohort A
Lisata Therapeutics has reported promising preliminary data from Cohort A of the Phase 2 ASCEND trial evaluating certepetide combined with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma. Notably, the treatment group displayed a median overall survival of 12.68 months compared to 9.72 months in the placebo group, along with four complete responses observed in the treatment group. Cohort B data is anticipated in the coming months, with plans to advance to Phase 3 trials projected for early 2026. The trial's protocol was optimized to adhere to international standards following Lisata’s acquisition of Cend Therapeutics.
Read more →LSTALisata Therapeutics to Present at the 2025 Sequire Investor Summit
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced that its CEO, Dr. David J. Mazzo, will present at the Sequire Investor Summit from January 21-23, 2025, in Puerto Rico. The presentation is scheduled for January 22 at 10:00 a.m. Atlantic Standard Time. Lisata is known for its innovative therapies aimed at treating advanced solid tumors and has a promising investigational drug candidate, certepetide, which aims to enhance the effectiveness of cancer treatment. The company expects to share significant milestones within the next year and a half.
Read more →LSTA▲ +6.6%on this news
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Lisata Therapeutics has announced the successful completion of patient enrollment in the Phase 1b/2a CENDIFOX trial, which is evaluating the iRGD cyclic peptide product candidate, certepetide. The trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, aims to assess the safety and efficacy of certepetide in combination with FOLFIRINOX for treating pancreatic, colon, and appendiceal cancers. With a total of 66 patients enrolled, Lisata anticipates valuable data collection from the trial and aims for results to be reported in 2025.
Read more →LSTALisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
Lisata Therapeutics has entered a global license agreement with Kuva Labs to enhance solid tumor imaging through the innovative use of Lisata's certepetide. Under the terms, Kuva will take on all development and commercialization costs for its NanoMark platform, while Lisata will provide certepetide. This partnership is expected to improve the accuracy of tumor detection, resulting in earlier treatment and potentially better patient outcomes. The agreement includes financial incentives such as an upfront license fee and future royalties.
Read more →LSTALisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
Lisata Therapeutics, Inc. has been recognized as the 'Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards for its innovative approach in the treatment of advanced solid tumors. The award highlights Lisata's commitment to addressing unmet medical needs and its successful use of the CendR Platform® technology to improve cancer therapies. Certepetide, their investigational drug, has shown promising results in enhancing chemotherapy efficacy for pancreatic cancer and has received various designations from the FDA. The recognition reflects the company's dedication to developing effective treatments for serious diseases.
Read more →LSTALisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call s
Lisata Therapeutics reported its third quarter 2024 financial results, highlighting significant advancements in its development pipeline, particularly with the investigational drug certepetide. The company anticipates multiple key data readouts in the coming 18 months, with current trials demonstrating certepetide's potential to improve treatment outcomes in various solid tumors. Notably, preliminary results from ongoing clinical trials are expected to yield critical data that could influence future treatment strategies. Lisata's fiscal management reflects a decrease in operating expenses year-over-year, suggesting a strategic approach to resource allocation amidst ongoing research efforts.
Read more →LSTALisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced it will report its third quarter financial results on November 12, 2024. The report will follow a conference call at 4:30 p.m. Eastern time for registered participants. The company is focused on advancing therapies for solid tumors and has established partnerships to support its research and development efforts. Lisata anticipates significant milestones in the coming years, reflecting ongoing progress in its clinical trials and operations.
Read more →LSTALisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics and Valo Therapeutics have announced a preclinical research collaboration to explore the combination of Lisata's certepetide with ValoTx's PeptiCRAd technology in melanoma treatment. This partnership aims to improve patient outcomes by leveraging the complementary mechanisms of action offered by their respective therapies. Certepetide has previously demonstrated synergistic effects with immunotherapies and is expected to enhance the effectiveness of existing cancer treatments. Both companies express optimism about the potential advancements in cancer therapy arising from this collaboration.
Read more →LSTALisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Lisata Therapeutics, a clinical-stage pharmaceutical company, has announced its participation in several industry and investor events in November 2024. Key representatives, including Vice President Tariq Imam and CEO David J. Mazzo, will present at BIO-Europe, PEGS Europe Summit, and the LSX Inv€$tival showcase. The company is known for its investigational drug, certepetide, designed to improve the efficacy of anti-cancer treatments. Additionally, Lisata aims to achieve significant milestones over the next year and a half and is well-positioned for future growth.
Read more →LSTALisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Lisata Therapeutics has announced a sponsored preclinical research agreement with the University of Cincinnati to explore the use of its novel cyclic peptide candidate, certepetide, in combination with bevacizumab to treat endometriosis. This collaboration seeks to leverage certepetide's targeted delivery mechanism, which could improve treatment outcomes for the 6.5 million women affected by the condition in the U.S. The potential efficacy of this combination therapy could provide insights that advance treatment options in the field.
Read more →LSTALisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
Lisata Therapeutics, Inc. has announced its participation in several upcoming industry and investor events throughout October 2024. The company will be represented by Tariq Imam at the Pharma Partnering U.S. Summit, while CEO David J. Mazzo will present at both the BioFuture and LD Micro Main Event. These engagements aim to enhance visibility and foster connections with potential partners and investors. Lisata Therapeutics, known for its innovative approach to treating solid tumors, anticipates significant milestones in the near future.
Read more →LSTA▲ +6.5%on this news
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Lisata Therapeutics has announced the treatment of the first patient in the second-line cholangiocarcinoma cohort of its BOLSTER trial. This follows successful enrollment in the first-line cohort, with the goal of evaluating the investigational drug certepetide in patients who have progressed after standard therapy. The trial aims to enhance therapeutic outcomes for cholangiocarcinoma patients, a cancer associated with a poor prognosis. Certepetide's mechanism involves targeting the tumor specifically, which could improve drug delivery and efficacy.
Read more →LSTALisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
Lisata Therapeutics, a clinical-stage pharmaceutical company, will participate in several key industry events in September 2024. The management, led by CEO David J. Mazzo, will present at the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 LSX World Congress USA. These presentations aim to showcase Lisata's innovative therapies for advanced solid tumors. The company is also expected to announce important milestones in its clinical development over the next 1.5 years.
Read more →LSTA▲ +9%on this newsshared move
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Lisata Therapeutics has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational drug, certepetide, for treating cholangiocarcinoma, a rare and aggressive cancer with limited treatment options. This designation is a crucial step toward providing innovative therapies for patients suffering from this condition. The company is evaluating certepetide in the BOLSTER trial, a Phase 2a study that aims to determine its efficacy for first- and second-line treatment of cholangiocarcinoma. The FDA's grant may facilitate faster development timelines and financial benefits for Lisata as it moves forward with clinical trials.
Read more →LSTALisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 2b ASCEND trial top-line data remains on track to be reported in fourth quarter of 2024 Available cash projected to fun
Lisata Therapeutics has reported its financial results for Q2 2024, highlighting ongoing advancements in its clinical studies involving the investigational drug certepetide. The company anticipates reporting topline data from its Phase 2b ASCEND trial in late 2024 and has confirmed sufficient cash to fund operations through early 2026. Certepetide has received important designations from regulatory bodies, supporting its potential in treating various cancers.
Read more →LSTA▼ -8.7%on this news
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics, Inc. will report its second quarter 2024 financial results on August 12, 2024. Following the report, a conference call will be held at 4:30 p.m. Eastern time for stakeholders to discuss the outcomes. The company is recognized for its innovative therapies targeting advanced solid tumors and has supportive partnerships that contribute to its operational funding through to early 2026. Further milestones in its clinical trials are anticipated in the coming years.
Read more →LSTALisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Lisata Therapeutics has successfully completed enrollment in its Phase 2a BOLSTER trial for certepetide in first-line cholangiocarcinoma, ahead of schedule by almost six months. The study, which evaluates certepetide in combination with standard care, highlights the urgent need for effective treatments in this difficult-to-treat cancer. The company plans to enroll the first patient in a new arm of the trial targeting second-line cholangiocarcinoma by late 2024. Top-line data results are expected by mid-2025, indicating significant progress in the development of this investigational therapy.
Read more →LSTALisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Lisata Therapeutics announced positive preclinical results for its investigational drug, certepetide, at the 2024 Cholangiocarcinoma Foundation Annual Conference. The study indicated that certepetide, combined with standard chemotherapy and immunotherapy, significantly prolonged survival for mice with intrahepatic cholangiocarcinoma. The company is advancing to Phase 2a trials, exploring additional combination therapies based on early encouraging results. Additionally, certepetide has demonstrated favorable safety and efficacy profiles, suggesting potential as a breakthrough treatment for this aggressive cancer.
Read more →LSTALisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Lisata Therapeutics has announced the full enrollment of the pancreatic cancer cohort in its Phase 1b/2a CENDIFOX trial. This trial, led by Dr. Anup Kasi at KU Cancer Center, evaluates the efficacy of certepetide combined with FOLFIRINOX-based therapies. The company aims to gather important data relating to safety and outcomes for patients with pancreatic, colon, and appendiceal cancers. Certepetide's ability to penetrate solid tumors effectively could enhance the efficacy of various treatment modalities. The trial is part of Lisata's broader efforts to develop innovative therapies for advanced solid tumors.
Read more →LSTALisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced its participation in the BIO International Convention and the GCFF 2024 Bio Investing Conference scheduled for June 2024. CEO David J. Mazzo will present at both events, highlighting the company's innovative therapies for treating advanced solid tumors. Lisata expects to achieve significant milestones over the next two years, which will be supported by its available capital until early 2026. This demonstrates the company's proactive approach to engage with investors and stakeholders in the biopharma industry.
Read more →LSTALisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
Lisata Therapeutics has been granted a Paediatric Investigation Plan waiver by the European Medicines Agency for its investigational product, certepetide, in treating pancreatic cancer. This waiver indicates that pediatric studies are unnecessary, allowing Lisata to streamline its development efforts and reduce the clinical trial burden and costs associated with bringing the drug to market. The EMA acknowledged that pancreatic cancer predominantly affects adults, justifying the waiver. Lisata remains committed to evaluating certepetide for other pediatric solid tumors as required.
Read more →LSTA▲ +5.9%on this news
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operat
Lisata Therapeutics announced its financial results for Q1 2024 and provided a business update, highlighting the anticipated topline data from the Phase 2b ASCEND trial expected in Q4 2024. The company affirmed that it has enough cash to fund operations into early 2026, which will cover all ongoing studies. Additionally, it received several FDA designations that support its investigational drug, certepetide, positioning the company favorably for upcoming trials and regulatory interactions.
Read more →LSTA▲ +5.9%on this newsshared move
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
Lisata Therapeutics will participate in several industry and investor events in May 2024, including the Pharma Partnering U.S. Summit and the BioNJ BioPartnering Conference. Representatives from the company, including VP Tariq Imam and CEO David J. Mazzo, will be available for one-on-one meetings with attendees. Although Lisata will not have a poster presentation at the ASCO Annual Meeting, they will be present for discussions with interested parties. The company is focused on developing advanced therapies for solid tumors.
Read more →LSTALisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
Lisata Therapeutics, Inc. announced that it will report its financial results for the first quarter of 2024 on May 9, 2024, and will host a conference call following the announcement. The company specializes in developing therapies for advanced solid tumors and plans to outline its ongoing business initiatives during the call. Investors can participate by registering online, with additional access provided through a live webcast. The company expects significant milestones regarding its lead product candidate certapetide in the coming years.
Read more →LSTALisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics and Qilu Pharmaceutical announced the treatment of the first patient in a Phase 2 trial of LSTA1 for metastatic pancreatic ductal adenocarcinoma in China. The trial aims to evaluate LSTA1 combined with standard chemotherapy compared to chemotherapy alone, enrolling up to 120 patients. Preliminary data from earlier trials suggest that LSTA1 may enhance survival rates, addressing the critical need for effective treatments in this aggressive cancer. This partnership signals significant advancements in the fight against pancreatic cancer in Greater China.
Read more →LSTALisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics announced that the U.S. FDA has granted Orphan Drug Designation to LSTA1 for the treatment of osteosarcoma, emphasizing the drug's potential impact on this rare cancer. This follows a previous designation for the same drug regarding pediatric cases. The designation provides advantages such as exclusive marketing rights and potential financial incentives. LSTA1 aims to improve the delivery of anti-cancer therapies through a novel uptake pathway and has shown promising results in clinical trials.
Read more →LSTALisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
Lisata Therapeutics, Inc. has announced participation in several key industry and investor events scheduled for April 2024. CEO David J. Mazzo will present at the LD Micro Invitational XIV and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, among others. These appearances reflect the company's commitment to engaging with investors and highlighting their clinical-stage therapies for advanced solid tumors. The events will facilitate one-on-one meetings with management for registered investors, enhancing communication and outreach.
Read more →LSTA▲ +8.4%on this news
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Lisata Therapeutics has announced that its lead product candidate, LSTA1, received Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma. This designation is significant as it underscores the urgent medical needs in pediatric cancer care. LSTA1 has demonstrated potential in both preclinical and clinical trials for various solid tumors. The FDA designation may also provide a priority review voucher that could expedite the approval process for new drug applications.
Read more →LSTA▼ -7.3%on this news
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operat
Lisata Therapeutics reported its full year 2023 financial results and provided a business update, highlighting key advancements in its clinical programs. The Phase 2b ASCEND trial of LSTA1 is fully enrolled, with top-line data expected in the fourth quarter of 2024, while operational funds are projected to sustain the company into early 2026. The report emphasized the reduced operational and R&D expenses compared to the previous year, reflecting operational efficiency. Additionally, the company is exploring conditional approvals for LSTA1 across multiple regions based on the upcoming trial results.
Read more →LSTALisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
Lisata Therapeutics, Inc. announced a conference call to discuss its financial results for the year ending December 31, 2023, scheduled for February 29, 2024. The call will take place at 4:30 p.m. Eastern Time, and interested participants must register in advance. The company is focused on developing therapies for advanced solid tumors and anticipates significant clinical and business milestones within the next two years.
Read more →LSTALisata Therapeutics to Present at BIO CEO & Investor Conference
Lisata Therapeutics, Inc. announced that its CEO, Dr. David J. Mazzo, will present at the BIO CEO & Investor Conference on February 26-27, 2024. The company is known for developing therapies for advanced solid tumors and expects to share significant clinical and business milestones in the coming years. Management will also hold one-on-one meetings with investors during the conference.
Read more →LSTALisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
Lisata Therapeutics, a clinical-stage pharmaceutical company, has announced that its CEO, David J. Mazzo, will present at the Sequire Investor Summit in Puerto Rico from January 23-25, 2024. The presentation is scheduled for January 24 at 10:00 AM Atlantic Standard Time. The company is focused on developing therapies for advanced solid tumors and expects to achieve numerous business milestones in the coming years, supported by its financial planning. More details on the summit can be found on the event's official website.
Read more →LSTALisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
Lisata Therapeutics has announced the treatment of the first patient in a Phase 2a trial evaluating its drug LSTA1 for glioblastoma multiforme (GBM). The double-blind, placebo-controlled study aims to assess LSTA1's effectiveness when added to standard care alongside temozolomide. Enrolled at Tartu University Hospital in Estonia, the trial intends to include 30 patients, with significant backing from Lisata for its execution. The company is optimistic about LSTA1's ability to improve outcomes in a disease that is notoriously difficult to treat.
Read more →LSTA▲ +7.9%on this news
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
Lisata Therapeutics announced the publication of a case report indicating a complete response in a metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 alongside standard-of-care therapy. This report, published in the Oncology & Cancer Case Reports Journal, emphasizes the potential effectiveness of LSTA1 in improving treatment outcomes for patients with advanced solid tumors. The case highlights how LSTA1 enhances tumor targeting and penetration when used in conjunction with traditional approaches, showcasing its promise for future cancer therapies.
Read more →LSTA▲ +12.6%on this news
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics has announced the completion of patient enrollment in its Phase 2b ASCEND trial for LSTA1, targeting metastatic pancreatic ductal adenocarcinoma. This milestone was reached six months earlier than initially projected, and top-line data from the study is anticipated in late 2024. The trial involves a comparison of standard treatments with LSTA1 to assess its effectiveness in improving progression-free survival rates. The results could pave the way for accelerated regulatory approvals and further trials.
Read more →LSTALisata Therapeutics to Present at NobleCon19 Investor Conference
Lisata Therapeutics, Inc. will present at the NobleCon19 Investor Conference on December 4, 2023, highlighting its clinical-stage developments in advanced solid tumors. CEO Dr. David J. Mazzo will make the presentation, and the company will also conduct one-on-one meetings with investors. The conference will occur at Florida Atlantic University in Boca Raton, FL. Lisata plans to announce various clinical study milestones and sustain its development plan funding into early 2026.
Read more →LSTA▼ -5.8%on this news
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
Lisata Therapeutics, a clinical-stage pharmaceutical company, has announced its participation in three important conferences scheduled for November 2023. CEO David J. Mazzo will present at the LSX Investival Showcase and will also engage in one-on-one meetings during the Jefferies London Healthcare Conference. The company is set to deliver a virtual presentation at the GCFF Virtual Healthcare Investment Conference later in the month. Lisata's lead candidate, LSTA1, aims to improve the targeting of anti-cancer drugs in solid tumors and the company anticipates announcing key milestones in its development soon.
Read more →LSTALisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Significant clinical progress achieved in studies evaluating LSTA1 including first patients treated in BOLSTER (3 solid tumor
Lisata Therapeutics reported its third quarter 2023 financial results, showcasing advancements in clinical studies for its lead product, LSTA1. Notably, the first patients were treated in the BOLSTER trial, and enrollment in the ASCEND study is nearing completion. LSTA1 received orphan drug designations in both the U.S. and Europe for malignant glioma and pancreatic cancer, enhancing its development potential. The company anticipates generating topline data from the ASCEND trial by late 2024, promising expedited progress towards clinical insights.
Read more →LSTALisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
Lisata Therapeutics, a clinical-stage pharmaceutical company, will report its third quarter 2023 financial results on November 2, 2023, followed by a conference call. The company focuses on developing therapies for advanced solid tumors and has partnerships that bolster its R&D efforts. The conference call details will be shared with registered participants, and a live webcast will also be available for broader access. Lisata anticipates announcing further clinical and business milestones in the upcoming years.
Read more →LSTALisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
Lisata Therapeutics has announced that the first patient has been treated in the cholangiocarcinoma cohort of its BOLSTER trial, which evaluates the investigational drug LSTA1. This Phase 2a trial aims to assess the drug's efficacy when combined with standard-of-care treatment in patients with specific advanced solid tumors. The BOLSTER trial is also designed to streamline the testing process across multiple cancer types. The company expresses optimism that LSTA1 could significantly enhance outcomes for patients diagnosed with cholangiocarcinoma, a rare and aggressive cancer.
Read more →LSTA▲ +6.6%on this news
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
Lisata Therapeutics has announced that its lead product candidate, LSTA1, has been granted orphan drug designation by the European Medicines Agency for the treatment of pancreatic cancer. This designation signifies the potential of LSTA1 in addressing the significant unmet medical needs associated with this high-mortality cancer. LSTA1 is undergoing multiple clinical studies and aims to improve the delivery of existing therapies for solid tumors. The company is optimistic about advancing the product and exploring its effectiveness further in solid tumor treatments.
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in October
Lisata Therapeutics, Inc. has announced its participation in two upcoming conferences in October, where CEO David J. Mazzo will present findings and engage in one-on-one meetings with investors. The conferences include the BioCentury-BayHelix East-West Biopharma Summit in Cambridge, MA, and BioFuture in New York City. Lisata is focused on developing innovative therapies for treating advanced solid tumors and has plans to reveal important clinical and business milestones over the next two years.
Read more →LSTA▼ -8%on this news
Lisata Therapeutics Announces Participation in InfoSec World 2023
Lisata Therapeutics, Inc. will have its Chief Information Officer, Gregory Berkin, participate in InfoSec World 2023 from September 25-27 in Lake Buena Vista, Florida. Berkin is scheduled to be a panelist for a keynote discussion focused on the implications of Artificial Intelligence in leadership. The discussion is timely, considering Lisata's commitment to advancing therapeutic technologies for serious illnesses. The company's lead product candidate is aimed at enhancing the effectiveness of anti-cancer drugs for solid tumors.
Read more →LSTALisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
Lisata Therapeutics has announced the treatment of the first patient in the head and neck squamous cell carcinoma cohort of their BOLSTER trial for LSTA1, a novel tumor-targeting peptide. This Phase 2a trial aims to evaluate the efficacy of LSTA1 in combination with standard-of-care treatments against advanced solid tumors. The trial, conducted across approximately 40 sites globally, expects to enroll a total of 120 patients by late 2024. The BOLSTER trial may expand treatment modalities for patients facing life-threatening cancers, leveraging the unique properties of the investigational drug LSTA1.
Read more →LSTA▲ +10.9%on this news
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics announced a positive outcome from the interim futility analysis of its ASCEND trial for LSTA1, a treatment for metastatic pancreatic ductal adenocarcinoma. The Independent Data Safety Monitoring Committee recommended continuing the trial without modification, signaling confidence in LSTA1's efficacy and safety. Enrollment in the trial is progressing rapidly, and complete enrollment is projected for the first half of 2024. This positive development showcases the potential of LSTA1 to improve treatment outcomes for patients with this serious disease.
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in September
Lisata Therapeutics, Inc. announced its participation in two upcoming conferences in September, where CEO David J. Mazzo will present. The first event is the H.C. Wainwright 25th Annual Global Investment Conference in New York City. The second event is the LSX World Congress USA in Boston. Lisata is focused on developing therapies for advanced solid tumors and other diseases, with expectations to share significant clinical and business milestones in the near future.
Read more →LSTALisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical d
Lisata Therapeutics has reported its financial results for the second quarter of 2023, highlighting significant advancements in its clinical studies and capital conservation measures. The extension of its cash runway is projected to support operations through the first quarter of 2026 without compromising its clinical development. A key highlight is the execution of a technology transfer agreement for its Tumor Penetrating Nanocomplex platform with Impilo Therapeutics. The company continues to develop its lead investigational product, LSTA1, in several ongoing and planned trials aimed at treating advanced solid tumors.
Read more →LSTALisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
Lisata Therapeutics has received Orphan Drug Designation from the U.S. FDA for its lead candidate, LSTA1, aimed at treating malignant glioma. This designation marks a significant recognition of the drug's potential to address critical patient needs in this aggressive cancer. The company plans to initiate a Phase 2a clinical study evaluating LSTA1 in glioblastoma multiforme, with the first patient expected to be treated in Q4 2023. This milestone highlights Lisata's ongoing commitment to developing innovative cancer therapies.
Read more →LSTALisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
Lisata Therapeutics, a clinical-stage pharmaceutical company, plans to report its second quarter 2023 financial results on August 14, 2023, after market trading. A conference call will be hosted on August 15 at 8:30 a.m. Eastern Time to discuss the results. The company is focused on developing innovative therapies for advanced solid tumors and has established important partnerships for its novel treatment approach. Lisata is poised to announce various clinical and business milestones in the coming years.
Read more →LSTALisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING RIDGE, NJ (
Lisata Therapeutics announced the retirement of Dr. Erkki Ruoslahti from its Board of Directors, effective July 11, 2023. Dr. Ruoslahti will continue his association with the company as a scientific advisor. His retirement is influenced by the demands of international travel and his confidence in the company's lead asset, LSTA1. The company expresses gratitude for Dr. Ruoslahti's significant contributions and looks forward to his continued guidance as they progress with their clinical and development milestones.
Read more →LSTALisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
Lisata Therapeutics, a clinical-stage pharmaceutical company, will present at the GCFF Innovation & Healthcare virtual conference on June 15, 2023. CEO David J. Mazzo is expected to provide an overview of the company, emphasizing their innovative therapies for treating advanced solid tumors. The company is optimistic about its lead product candidate, LSTA1, which targets solid tumors more effectively. Lisata has established significant partnerships and is funded through key milestones expected in the coming years.
Read more →LSTALisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
Lisata Therapeutics has announced protocol enhancements to its ongoing Phase 2b ASCEND trial of LSTA1 for treating metastatic pancreatic ductal adenocarcinoma. The trial now includes a second cohort to evaluate an additional dose of LSTA1, increasing target enrollment to 155 subjects. The results from this trial may inform future Phase 3 studies and explore conditional approvals globally, with futility analysis results expected in Q3 2023. The trial is fully funded and is on track to complete enrollment by Q2 2024.
Read more →LSTALisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Conference call scheduled for today at 4 30 p.m. Eastern time BASKING RIDGE, NJ (
Lisata Therapeutics, Inc. reported its first quarter financial results for 2023 and provided updates on its clinical studies. The company announced significant milestones, including the treatment of the first patient in the iLSTA trial for pancreatic cancer. While research expenses declined slightly, net losses increased due to rising administrative costs. The company remains optimistic about its drug candidates, particularly LSTA1 in ongoing trials and potential partnerships for further developments.
Read more →LSTALisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
Lisata Therapeutics, Inc. will announce its first quarter 2023 financial results on May 9, 2023, and host a conference call at 4:30 p.m. Eastern Time. Interested participants are encouraged to register in advance for the call, which will also be available via live webcast on the company's website. The company's lead product candidate, LSTA1, is focused on enhancing drug delivery for solid tumors while minimizing impact on normal tissues. Positive clinical trial results suggest LSTA1 could improve treatment outcomes for patients with advanced solid tumors.
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in May
Lisata Therapeutics has announced its participation in three upcoming conferences in May 2023, where CEO David J. Mazzo will present. These conferences include live presentations in London and Dublin, as well as a virtual event. The participation aims to increase engagement with investors and highlight Lisata's innovative therapies for advanced solid tumors. The company continues to develop its lead product candidate, LSTA1, which has demonstrated promising results in clinical trials.
Read more →LSTALisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
Lisata Therapeutics has announced that it has been awarded $2.2 million in non-dilutive funding as part of the New Jersey Technology Business Tax Certificate Transfer Program. This program allows biotech companies to convert net operating losses and research tax credits into capital funds. CEO David J. Mazzo expressed gratitude for ongoing support from the New Jersey Economic Development Authority, emphasizing that the capital will enhance the company's clinical development efforts. Over the last four years, Lisata has received nearly $18 million through this initiative.
Read more →LSTALisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
Lisata Therapeutics and WARPNINE have announced the successful treatment of the first patient in the iLSTA Trial, which tests LSTA1 alongside standard chemotherapy and immunotherapy for patients suffering from locally advanced non-resectable pancreatic ductal adenocarcinoma. This 30-patient trial aims to assess LSTA1's safety and pharmacodynamics as it is administered with durvalumab and other agents. With the support of WARPNINE, the trial seeks to innovate treatment for a disease that has historically been challenging to treat effectively.
Read more →LSTALisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4 30 p.m. Eastern time BASKING RIDGE, NJ (
Lisata Therapeutics reported its fourth quarter and full year 2022 financial results, revealing significant changes and ongoing clinical trials for its product candidates. The company believes its lead candidate, LSTA1, could transform cancer treatment by enhancing drug delivery to solid tumors. Financial highlights show a decrease in research and development expenses compared to the previous year. However, challenges such as patient enrollment issues for the XOWNA trial and the need for further funding for LSTA201's development were noted.
Read more →LSTALisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
Lisata Therapeutics, Inc. will announce its financial results for Q4 and the full year of 2022 on March 30, 2023, after market close. A conference call will be held at 4:30 p.m. Eastern Time, where participants need to register in advance. The company is known for developing innovative therapies targeting advanced solid tumors, particularly through its lead candidate, LSTA1. It has shown favorable results in clinical trials for pancreatic cancer and aims to enhance the efficacy of anti-cancer drugs.
Read more →LSTA▲ +9%on this news
Lisata Therapeutics to Webcast Live at the Life Sciences Investor Forum on March 9th
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced its upcoming live presentation at the Life Science Investor Forum on March 9, 2023. The forum is hosted by VirtualInvestorConferences.com and will showcase Lisata's work in developing therapies for advanced solid tumors. The company is particularly focused on its lead product candidate, LSTA1, which aims to improve the delivery of anti-cancer drugs directly to tumors. Clinical trials have reported favorable safety and efficacy outcomes for LSTA1 in treating pancreatic cancer.
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in February
Lisata Therapeutics, a clinical-stage pharmaceutical company, has announced its participation in two key conferences in February. CEO David J. Mazzo will present at the 2023 BIO CEO & Investor Conference, while President David S. Slack will present at Biocom California's Global Life Science Partnering & Investor Conference. Both events include opportunities for management to engage with investors. The company’s lead product, LSTA1, is in development for advanced solid tumors and has demonstrated positive results in trials.
Read more →LSTALisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference call scheduled for today at 4:30 p.m. Eastern time Post-merger profile describes rich clinical development pipeline backed by solid financial situation Qilu Pharmaceutical Phase 1b/2 study of LSTA1 in China ongoing; Preliminary data expected in the second half of 202
Read more →LSTAto Lisata's Amendment No. 1 to Current Report on Form 8-K filed on
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4 30 p.m. Eastern time Post-merger profile describes rich clinical development pipeline backed by solid financial situation Qilu Pharmaceutical
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
BASKING RIDGE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announ
Read more →LSTA▼ -5.5%on this newsshared move
Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announ
Read more →LSTALisata Therapeutics Announces Participation in Upcoming Conferences in October 2022
BASKING RIDGE, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today ann
Read more →LSTACEND BUSINESS Overview Cend Therapeutics, Inc. (formerly DrugCendR, Inc.) is a Delaware corporation, formed in October 2015 ("Cend" or "the Company") and based in San Diego, California. Cend is focused on a tumor microen
Cend Therapeutics, Inc. (formerly DrugCendR, Inc.) is a Delaware corporation, formed in October 2015 ("Cend" or "the Company") and based in San Diego, California. Cend is focused on a tumor microenvironment ("TME")-modifying approach to enable more effective treatment for a rang
Read more →LSTALisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award
BASKING RIDGE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today an
Read more →LSTACaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics Company to commence trading on The Nasdaq Capital Market under Ticker Symbol "LSTA" Lisata has approximately $76 million in cash and investments following transaction
Read more →LSTACaladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, NJ (
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, NJ (September 14, 2022) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"
Read more →LSTACaladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference c
Read more →LSTACaladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA in Coronary Microvascular Dysfunction Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-con
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA in Coronary Microvascular Dysfunction Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA to
Read more →LSTACaladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Mainta
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expandin
Read more →LSTACaladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed compa
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong ex
Read more →LSTACaladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2022) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"),
Read more →LSTACaladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Confe
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4 30 p.m. Eastern time BASKING
Read more →LSTACaladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern Time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern Time BASKING RIDGE, N.J. (August 5, 2021) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"), a clinical-st
Read more →LSTACaladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern Time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update Conference call begins today at 4 30 p.m. Eastern Time BASKING RIDGE, N.J. (May 6, 2021) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"), a clinical-stage
Read more →LSTACaladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Company demonstrates resilience despite COVID-19 challenges Financial situation secure and development progra
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Company demonstrates resilience despite COVID-19 challenges Financial situation secure and development programs progressing Conference call begins today at 4 30 p.m. (
Read more →LSTACaladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (February 12, 2021) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company de
Read more →LSTAThis Investor Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the d
David J. Mazzo, PhD President & Chief Executive Of ficer Developing Regenerative Therapies that Reverse Chronic Disease J a n u a r y 2 9 , 2 0 21 | N a s d a q : C L B S Exhibit 99.1 This Investor Presentation contains forward-looking statements within the meaning of the Privat
Read more →LSTACaladrius Biosciences Announces $25.0 Million Private Placement BASKING RIDGE, N.J. (
Caladrius Biosciences Announces $25.0 Million Private Placement BASKING RIDGE, N.J. (January 21, 2021) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies design
Read more →LSTACaladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J. (
Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer BASKING RIDGE, N.J. (November 17, 2020) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Co
Read more →LSTACaladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results Conference call begins today at 4 30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results Conference call begins today at 4 30 p.m. Eastern time BASKING RIDGE, N.J. (November 5, 2020) - Caladrius Biosciences, Inc. (Nasdaq CLBS) ("Caladrius" or the "Company"), a clinical-
Read more →LSTACaladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results Clinical programs advanced and expanded with strengthened cash position Conference call begins today at 4 30 p.m. Eastern
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results Clinical programs advanced and expanded with strengthened Conference call begins today at 4 30 p.m. Eastern time BASKING RIDGE, N.J. (August 13, 2020) - Caladrius Biosciences, Inc
Read more →LSTACaladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors BASKING RIDGE, N.J. (
Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors BASKING RIDGE, N.J. (July 28, 2020) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular ther
Read more →LSTACaladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (May 26, 2020) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to
Read more →LSTACaladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ c
Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringin
Read more →LSTACaladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (April 23, 2020) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated
Read more →LSTACaladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program BASKING RIDGE, N.J. (
Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program BASKING RIDGE, N.J. (April 22, 2020) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), today announced that
Read more →LSTACaladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly s
Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly statistically significant improvement in coronary flow reser
Read more →LSTACaladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019 Single administration of CLBS16 durably improves heart function and symptoms with
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019 Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows
Read more →LSTACaladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 6, 2019) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Compan
Read more →LSTACaladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Con
Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKI
Read more →LSTACaladrius Biosciences, Inc. Reports 2019 First Quarter Financial Results and Provides Corporate Update All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD a
Caladrius Biosciences, Inc. Reports 2019 First Quarter Financial Results and Provides Corporate Update All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targe
Read more →LSTACaladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 14, 2019) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics de
Read more →LSTACaladrius Biosciences Reports 2018 Third Quarter Financial Results Development programs remain on track accompanied by continued strong fiscal management Conference call begins today at 4:30 p.m. Eastern time BASKING RID
Caladrius Biosciences Reports 2018 Third Quarter Financial Results Development programs remain on track accompanied by continued strong fiscal management Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 8, 2018) - Caladrius Biosciences, Inc
Read more →LSTACaladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 9, 2018) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a development-stage
Read more →LSTACaladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina BASKING RIDGE, N.J. (
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina BASKING RIDGE, N.J. (June 19, 2018) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical com
Read more →LSTACaladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (March 22, 2018) - Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a development-stage biopharm
Read more →LSTACaladrius Biosciences Announces Enrollment of the 70 th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes Milestone Achievement Triggered $2.4 Million Payments to Caladrius BASKING RIDGE, N.J. (
Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes Milestone Achievement Triggered $2.4 Million Payments to Caladrius BASKING RIDGE, N.J. (September 5, 2017) - Caladrius Biosciences, Inc. (NASDAQ: CLB
Read more →LSTACaladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results Annual revenue growth of 57% exceeds 2016 financial guidance Conference call begins today at 8:30 am Eastern time BASKING RIDGE, N.J., (
Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results Annual revenue growth of 57% exceeds 2016 financial guidance Conference call begins today at 8:30 am Eastern time BASKING RIDGE, N.J., (March 17, 2017) - Caladrius Biosciences, Inc. (NASDAQ: CL
Read more →LSTASupport Agreement and Irrevocable Proxy This Support Agreement and Irrevocable Proxy (this " Agreement ") is entered into as of
Agreement and Irrevocable Proxy Agreement and Irrevocable Proxy (this "Agreement") is entered into as of March 16, 2017, by and between HITACHI CHEMICAL CO. AMERICA, LTD., a New York corporation ("Purchaser"), and the undersigned stockholder ("Stockholder") of CALADRIUS BIOSCI
Read more →LSTACaladrius Biosciences Updates Status of Receipt of Funds for a Portion of Previously Announced Private Placement
Caladrius Biosciences Updates Status of Receipt of Funds for a Portion of Previously Announced Private Placement BASKING RIDGE, N.J., Jan. 6, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a cell therapy company combining a sel
Read more →LSTACaladrius Biosciences Reports 2016 Third Quarter Financial Results Revenues Increase 58% Versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J. (
Caladrius Biosciences Reports 2016 Third Quarter Financial Results Revenues Increase 58% Versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J. (November 7, 2016) - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a
Read more →LSTACaladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors Experienced industry leader brings significant biopharmaceutical financing and investment expertise
Caladrius Biosciences Appoints Gregory R. Brown, MD, to its Board of Directors Experienced industry leader brings significant biopharmaceutical financing and investment expertise BASKING RIDGE, N.J., October 12, 2016 - Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or t
Read more →LSTACaladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants $21 Million in Private Placements, Funded in Two Tranches, Including $5 Million from Sanford Heal
Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in Common Equity Priced At Market Without Warrants $21 Million in Private Placements, Funded in Two Tranches, Including $5 Million from Sanford Health to Support Type 1 Diabetes Candidate Development $4 Mi
Read more →LSTACaladrius Biosciences Reports 2016 Second Quarter Financial Results Total Quarterly Revenues Increase 41% and Expenses Decrease 50% versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.
Caladrius Biosciences Reports 2016 Second Quarter Financial Results Total Quarterly Revenues Increase 41% and Expenses Decrease 50% versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J. (August 9, 2016) - Caladrius Biosciences, Inc. (NASDAQ
Read more →LSTAQ1 EARNINGS PR Exhibit Caladrius Biosciences Reports 2016 First Quarter Financial Results Total Quarterly Revenues Increase 136% versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J.
Caladrius Biosciences Reports 2016 First Quarter Financial Results Total Quarterly Revenues Increase 136% versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J. (May 5, 2016) - Caladrius Biosciences, Inc. (NASDAQ: CLBS) ("Caladrius"), a cell
Read more →LSTACaladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance Emphasizes PCT subsidiary's leadership position in the emerging cell therapy market with expectations for 30% revenue growth in 2016 Focuses clinical
Caladrius Tightens Strategic Focus and Provides 2016 Revenue Guidance BASKING RIDGE, N.J. (January 6, 2016) - Caladrius Biosciences, Inc. ("Caladrius" or the "Company") (NASDAQ: CLBS), a cell therapy company combining an industry-leading development and manufacturing services pr
Read more →LSTACaladrius Biosciences Announces Third Quarter 2015 Financial Results and Provides Corporate Update Revenues Increase 43% Driven by Growth in Clinical Services at PCT Subsidiary
Caladrius Biosciences Announces Third Quarter 2015 Financial Results and Provides Corporate Update Revenues Increase 43% Driven by Growth in Clinical Services at PCT Subsidiary BASKING RIDGE, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Ca
Read more →LSTANeoStem Announces Proposed Public Offering of Common Stock
NeoStem Announces Proposed Public Offering of Common Stock NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use th
Read more →LSTANeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results Results support previous observation of dose-dependent signals across multiple endpoints New York, NY (
NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results Results support previous observation of dose-dependent signals across multiple endpoints New York, NY (March 16, 2015) - NeoStem, Inc. (NASDAQ:NBS), a biopharmaceutical company developing novel cell based
Read more →LSTANeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive Officer and Robert S. Vaters as President and Chief Financial Officer and Elects Robin Smith, MD to Executive Chair of
NeoStem Strengthens Executive Management With Appointments of David J. Mazzo, PhD as Chief Executive Officer and Robert S. Vaters as President and Chief Financial Officer and Elects Robin Smith, MD to Executive Chair of the Board NEW YORK, Jan. 5, 2015 (GLOBE NEWSWIRE) -- NeoSte
Read more →LSTANeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial Statistically significant mortality benefit observed in patients with acute myocardial infarction (AMI) treated with intracoronary administ
NeoStem Announces Initial Positive Data from Phase 2 PreSERVE AMI Clinical Trial Statistically significant mortality benefit observed in patients with acute myocardial infarction (AMI) treated with intracoronary administration of CD34 cells (NBS10; AMR-001) as well as statistica
Read more →LSTANeoStem Announces Third Quarter 2014 Financial Results and Outlines Near Term Milestones
NeoStem Announces Third Quarter 2014 Financial Results and Outlines Near Term Milestones NEW YORK, Oct. 30, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, today
Read more →LSTANeoStem Secures Debt Facility Strengthens Balance Sheet with Non-Dilutive Financing Company Provides Update on Remaining Milestones for 2014
NeoStem Secures Debt Facility Strengthens Balance Sheet with Non-Dilutive Financing Company Provides Update on Remaining Milestones for 2014 NEW YORK, September 29, 2014 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy indus
Read more →LSTANeoStem Announces Second Quarter 2014 Financial Results and Provides Business Update
NeoStem Announces Second Quarter 2014 Financial Results and Provides Business Update NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, today provided an update on the progress of its business and reported s
Read more →LSTANeoStem Appoints Steven M. Klosk to Board of Directors
NeoStem Appoints Steven M. Klosk to Board of Directors NEW YORK, NY, July 8, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS), a leader in the emerging cellular therapy industry, announced today the appointment of Steven M. Klosk to its Board of Directors. Mr. Klosk is a sea
Read more →LSTANeoStem Presents Five-Year Survival Data for Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells at American Society of Clinical Oncology Annual Meeting -- Pooled Analysis of Early-Phase Studies Indicates Melap
NeoStem Presents Five-Year Survival Data for Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells at American Society of Clinical Oncology Annual Meeting -- Pooled Analysis of Early-Phase Studies Indicates Melapuldencel-T, an Investigational Immunotherapy for Metastatic
Read more →LSTANeoStem Announces Closing of Acquisition of California Stem Cell, Inc. and First Quarter 2014 Financial Results 61% Revenue Increase Over First Quarter 2013
NeoStem Announces Closing of Acquisition of California Stem Cell, Inc. and First Quarter 2014 Financial Results 61% Revenue Increase Over First Quarter 2013 NEW YORK, May 8, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emergi
Read more →LSTANeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc. Addition of a Phase 3 ready immunotherapy targeting the cancer initiating cells for melanoma
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc. Addition of a Phase 3 ready immunotherapy targeting the cancer initiating cells for melanoma NEW YORK, April 14, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a lead
Read more →LSTANeoStem Announces Conference Call and Webcast
NeoStem Announces Conference Call and Webcast NEW YORK, April 11, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that it plans to conduct a conference call and webcast. The cal
Read more →LSTANeoStem Announces 2013 Year End Financial Results and Provides Corporate Update Expanded Clinical Development Programs With Near Term Data
NeoStem Announces 2013 Year End Financial Results and Provides Corporate Update Expanded Clinical Development Programs With Near Term Data NEW YORK, March 13, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company") today announced 2013 year end results
Read more →LSTANeoStem Completes Patient Enrollment in Phase 2 AMR-001 Trial for Prevention of Adverse Cardiovascular Events Following a Heart Attack PreSERVE AMI Data Readout Expected in Third Quarter 2014
NeoStem Completes Patient Enrollment in Phase 2 AMR-001 Trial for Prevention of Adverse Cardiovascular Events Following a Heart Attack PreSERVE AMI Data Readout Expected in Third Quarter 2014 NEW YORK, Dec. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or t
Read more →LSTANeoStem Announces Third Quarter 2013 Financial Results and Provides Corporate Update Company Now Has Cash Reserves in Excess of $50 Million
NeoStem Announces Third Quarter 2013 Financial Results and Provides Corporate Update Company Now Has Cash Reserves in Excess of $50 Million NEW YORK, November 7, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular
Read more →LSTANeoStem Announces Pricing of Public Offering of Common Stock
NeoStem Announces Pricing of Public Offering of Common Stock NEW YORK, October 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the pricing of an underwritten public offering
Read more →LSTAExh. 99.1_PR 10-3-13 NeoStem Announces Proposed Public Offering of Common Stock
NeoStem Announces Proposed Public Offering of Common Stock NEW YORK, October 3, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced that it intends to offer for sale shares of its c
Read more →LSTANeoStem Announces Second Quarter 2013 Financial Results, Highlights and Developments Company on Track to Complete Enrollment of its PreSERVE Phase 2 Clinical Trial for AMR-001 in 2013
NeoStem Announces Second Quarter 2013 Financial Results, Highlights and Developments Company on Track to Complete Enrollment of its PreSERVE Phase 2 Clinical Trial for AMR-001 in 2013 NEW YORK, August 8, 2013 -- NeoStem, Inc. (NASDAQ: NBS) (or the "Company"), a leader in the em
Read more →LSTANeoStem Begins Trading Today on NASDAQ Stock Market NeoStem to Ring The NASDAQ Stock Market Opening Bell on
NeoStem Begins Trading Today on NASDAQ Stock Market NeoStem to Ring The NASDAQ Stock Market Opening Bell on August 7, 2013 NEW YORK, August 5, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cell therapy market, today announced that the Company w
Read more →LSTANeoStem Appoints Douglas W. Losordo as Chief Medical Officer Andrew L. Pecora to Assume New Role as Chief Visionary Officer
NeoStem Appoints Douglas W. Losordo as Chief Medical Officer Andrew L. Pecora to Assume New Role as Chief Visionary Officer NEW YORK, August 6, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NASDAQ:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, an
Read more →LSTANeoStem to Begin Trading on NASDAQ Stock Market Ticker Symbol Will Remain "NBS"
NeoStem to Begin Trading on NASDAQ Stock Market Ticker Symbol Will Remain "NBS" NEW YORK, July 23, 2013 - NeoStem, Inc. (NYSE MKT: NBS), a leader in the emerging cell therapy market, today announced that it has met the listing criteria for the NASDAQ Capital Market and will mov
Read more →LSTANeoStem Announces 1-for-10 Reverse Split
NeoStem Announces 1-for-10 Reverse Split NEW YORK, July 12, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cell therapy market, announced that it is effecting a 1-for-10 reverse stock split of its common stock which w
Read more →LSTANeoStem CEO's Letter to Shareholders
NeoStem CEO's Letter to Shareholders NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- We at NeoStem, Inc. (NYSE MKT: NBS) believe that cell therapy has the potential to radically change the face of how diseases are treated, leading to longer and, more importantly, higher quality lives
Read more →LSTANeoStem Announces Partial Exercise of Underwriters' Over-Allotment Option
NeoStem Announces Partial Exercise of Underwriters' Over-Allotment Option NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT: NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the partial exercise of the over-a
Read more →LSTANeoStem Announces 2012 Year End Financial Results and Business Update - Revenues increased by 43% - New York
NeoStem Announces 2012 Year End Financial Results and Business Update - Revenues increased by 43% - New York, March 11, 2013-- NeoStem, Inc. (NYSE MKT: NBS) ("NeoStem" or the "Company") today announced 2012 year end results and provided a business update. NeoStem is a leader in
Read more →LSTANeoStem Appoints Stephen W. Potter to Board of Directors
NeoStem Appoints Stephen W. Potter to Board of Directors NEW YORK, February 11, 2013 (GLOBE NEWSWIRE) - NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the appointment of Stephen W. Potte
Read more →LSTANeoStem Announces Quarterly Results and Business Update
NeoStem Announces Quarterly Results and Business Update NEW YORK, Nov. 14, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company") today announced third quarter results and provided a business update. NeoStem is emerging as a market leader in the fast
Read more →LSTAPR_Series E Redemption NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock
NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock NEW YORK, Oct. 17, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that it will r
Read more →LSTANeoStem Signs a Definitive Agreement to Divest Its 51% Ownership Interest in Suzhou Erye
NeoStem Signs a Definitive Agreement to Divest Its 51% Ownership Interest in Suzhou Erye NEW YORK, June 18, 2012 (GLOBE NEWSWIRE) - NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company") today announced that the Company has entered into a definitive agreement to sell its
Read more →LSTAPRESENTATION Investor Presentation NYSE Amex: NBS April 2012 2 Included in this presentation are "forward - looking" statements within the meaning of the Private Securities Litigation Reform Ac t of 1995, as well as hist
Investor Presentation NYSE Amex: NBS April 2012 2 Included in this presentation are "forward - looking" statements within the meaning of the Private Securities Litigation Reform Ac t of 1995, as well as historical information. Such forward - looking statements involve known and
Read more →LSTANeoStem Announces Pricing of Public Offering for $6,000,000 in Gross Proceeds
NeoStem Announces Pricing of Public Offering for $6,000,000 NEW YORK, March 29, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or "the Company") a leader in the cell therapy industry, announced today the pricing of an underwritten public offering of 15,000,
Read more →LSTANeoStem Provides Updates and Reports Year End Results
NeoStem Provides Updates and Reports Year End Results NEW YORK, March. 20, 2012 -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or "the Company") is a leader in the cell therapy industry, developing cell based therapeutics supported by the Company's expertise in contract manufact
Read more →LSTANeoStem, Inc. ("NBS") Investor Presentation January 2012 2 Included in this presentation are "forward - looking" statements within the meaning of the Private Securities Litigation Reform Ac t of 1995, as well as historic
NeoStem, Inc. ("NBS") Investor Presentation January 2012 2 Included in this presentation are "forward - looking" statements within the meaning of the Private Securities Litigation Reform Ac t of 1995, as well as historical information. Such forward - looking statements involve k
Read more →LSTAUnassociated Document Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing ALLENDALE, N.J.
Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing ALLENDALE, N.J., Jan. 12, 2012 /PRNewswire/ -- NeoStem's cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), a NeoStem, Inc. company (NYSE Amex: NB
Read more →LSTAAmorcyte, a NeoStem Company, Announces Expansion of Intellectual Property Coverage
Amorcyte, a NeoStem Company, Announces Expansion of Intellectual Property Coverage NEW YORK , Jan. 10, 2012 /PRNewswire/ -- Amorcyte, Inc. ("Amorcyte"), a NeoStem, Inc. company (NYSE Amex: NBS) ("NeoStem" or the "Company"), today announced the expansion of intellectual property
Read more →LSTAUnassociated Document NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations
NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations NEW YORK , Nov. 11, 2011 /PRNewswire/ --NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell based ther
Read more →LSTANeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company NEW YORK, Oct. 17, 2011 -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, and Amor
Read more →LSTANeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm NEW YORK, Aug. 23, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic develop
Read more →LSTAUnassociated Document NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter Press Release Source: NeoStem, Inc. On Monday
NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter Press Release Source: NeoStem, Inc. On Monday August 15, 2011, 9:06 am EDT NEW YORK, Aug. 15, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an intern
Read more →LSTAUnassociated Document NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds NEW YORK, July 22, 2011 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company, today announced the closing of an underwritte
Read more →LSTAUnassociated Document NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds NEW YORK, NY, July 19, 2011/PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company, announced today the pricing of an underwri
Read more →LSTAv225802_ex99-2 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
v225802_ex99-2 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing
Read more →LSTACapacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA Jun 13 2011 NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS ), an international bi
Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with product and service revenues, global resear
Read more →LSTAUnassociated Document NeoStem Provides Results for 2010 and an Update on Recent Activities Press Release Source: NeoStem, Inc. On Friday
NeoStem Provides Results for 2010 and an Update on Recent Activities Press Release Source: NeoStem, Inc. On Friday April 1, 2011, 9:15 am EDT NEW YORK, April 1, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical
Read more →LSTANeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development Mar 7 2011 NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and Ch
NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce that Jason Kolbert has joined the firm as
Read more →Competitive Position
How LSTA ranks across every disease it competes inCompetitive Position is a premium feature
See how LSTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial